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Introduction {#jdi12781-sec-0005}
============

Type 2 diabetes is characterized by chronic hyperglycemia caused by a combination of insulin resistance and insufficient insulin secretion. Sodium--glucose cotransporter‐2 (SGLT2) inhibitors have recently been developed as novel therapeutic agents for the treatment of type 2 diabetes[1](#jdi12781-bib-0001){ref-type="ref"}, [2](#jdi12781-bib-0002){ref-type="ref"}. These drugs inhibit the reabsorption of glucose in the proximal tubules of the kidney, leading to increased urinary excretion of glucose and decreased levels of blood glucose in diabetes patients[1](#jdi12781-bib-0001){ref-type="ref"}, [2](#jdi12781-bib-0002){ref-type="ref"}. In addition, SGLT2 inhibitors reportedly improve muscle insulin resistance and accelerate lipolysis in adipose tissue. Thus, use of SGLT2 inhibitors results in decreased bodyweight and visceral fat mass, and reduced blood pressure.

Empagliflozin (EMPA) is a potent and highly selective inhibitor of SGLT2 used in the treatment of type 2 diabetes. In a secondary prevention study (the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients \[EMPA‐REG OUTCOME^®^\] trial), EMPA successfully suppressed composite adverse cardiovascular (CV) outcomes[3](#jdi12781-bib-0003){ref-type="ref"}. In EMPA‐REG OUTCOME^®^ study, the reductions in the risk of CV/mortality outcomes with EMPA occurred early, suggesting that the benefits were not primarily driven by an effect on atherosclerosis. The mechanisms behind the CV benefits of EMPA are believed to be multifactorial and might involve its beneficial effects on insulin sensitivity, because the failing heart appears to be insulin resistant[4](#jdi12781-bib-0004){ref-type="ref"}.

A method for measuring remnant‐like particle cholesterol (RLP‐C), which reflects the levels of various kinds of the remnant lipoproteins in the blood[5](#jdi12781-bib-0005){ref-type="ref"}, has been established, and several studies have shown that RLP‐C has a significant correlation with insulin resistance. In the present study, we measured the effect of EMPA on RLP‐C levels and investigated whether RLP‐C is associated with insulin resistance in type 2 diabetes patients who have insulin resistance.

Methods {#jdi12781-sec-0006}
=======

Study design {#jdi12781-sec-0007}
------------

The present study was an open‐label, single‐center, prospective study. Empagliflozin (10 mg) or a placebo was administered once daily for 12 weeks as add‐on therapy without any other concurrent changes in medication. In both groups, established oral hypoglycemic drugs (sulfonylureas, metformin or an α‐glucosidase inhibitor), antihypertensive drugs (angiotensin II receptor blockers or calcium channel blockers) and antihyperlipidemic drugs (statins or fibrates) were continued. This protocol was approved by the ethics committees of Tohto Clinic, Tokyo, Japan, and designed in compliance with the principles embodied by the Declaration of Helsinki (2013). All patients provided written informed consent before all procedures related to this study. This study is registered with UMIN‐CTR (UMIN000021552).

Patients {#jdi12781-sec-0008}
--------

Type 2 diabetes patients without any history of taking SGLT2 inhibitors whose glycated hemoglobin (HbA1c) was \> 6.5%, despite receiving instruction regarding diet, exercise and medical treatment except SGLT2 inhibitors for at least 12 weeks at our clinic, and who might have insulin resistance (body mass index \[BMI\] \> 28 or homeostatic model assessment of insulin resistance \[HOMA‐IR\] \> 1.73 or fasting immunoreactive insulin \[IRI\] \> 10 and fasting blood glucose \< 180) were enrolled in the present study. A total of 60 patients were enrolled each in the placebo group and in the EMPA group. At the start of the study, the criteria for participating in this study applied to each patient again. As a consequence, five patients in the placebo group and two patients in the EMPA group were excluded because of the history of taking of SGLT2. Four patients in the placebo group were excluded because they were poorly controlled. Finally, the present study included 109 participants (70 men and 39 women, aged 38--74 years) who were allocated to receive EMPA (*n* = 58) or a placebo (*n* = 51).

Measurements {#jdi12781-sec-0009}
------------

Overnight fasting blood and urine samples were obtained before and 12 weeks after the administration of EMPA or a placebo. All biochemical data were obtained by measurement in our laboratory, except IRI, RLP‐C, brain natriuretic peptide, high‐sensitivity C‐reactive protein and urine albumin, which were measured by LSI Medicine Corporation (Tokyo, Japan). HOMA‐IR in the EMPA group at 12 weeks was calculated as follows: 12 weeks after the administration of EMPA, EMPA administration was stopped temporarily for 72 h until no urine glucose was detected. Fasting blood samples were then obtained, and blood glucose and IRI were measured.

Statistical analysis {#jdi12781-sec-0010}
--------------------

Data were expressed as mean ± standard deviation or percentage change after treatment. Statistical analyses were carried out using statistical software (EZR version 1.21; Saitama Medical Center, Jichi Medical University, Saitama, Japan)[6](#jdi12781-bib-0006){ref-type="ref"}. Comparison of parameters before and after treatment was carried out using the paired *t*‐test, and for intergroup comparisons the unpaired *t*‐test was used. To determine the factors associated with the change in RLP‐C, multiple linear regression analysis was carried out. The Pearson correlation coefficient test was carried out between the change in RLP‐C and HOMA‐IR. Differences were considered statistically significant at values of *P* \< 0.05.

Results {#jdi12781-sec-0011}
=======

The study included 109 participants who were randomly allocated to receive EMPA (*n* = 58) or a placebo (*n* = 51). Table [1](#jdi12781-tbl-0001){ref-type="table"} lists the general characteristics and blood biochemical measurements at baseline and at 12 weeks after initiating treatment with EMPA (EMPA group) or a placebo (placebo group). In the EMPA group, EMPA treatment for 12 weeks significantly reduced bodyweight (from 83.55 ± 17.9 kg to 80.68 ± 18.4 kg) and BMI (from 30.71 ± 4.72 to 29.58 ± 4.85). Reductions in fasting blood glucose (from 134.7 ± 27.3 to 124.0 ± 20.8 mg/dL) and HbA1c (from 7.37 ± 1.34 to 6.97 ± 0.94%) were observed, and reductions in fasting IRI (from 10.59 ± 5.83 to 9.13 ± 5.57 μU/mL) and in HOMA‐IR (from 3.03 ± 1.97 to 2.33 ± 1.95) were also observed at 12 weeks. The level of low‐density lipoprotein cholesterol (LDL‐C) was not altered, whereas HDL cholesterol (HDL‐C) significantly increased and triglyceride was significantly reduced. Importantly, RLP‐C was also significantly decreased (from 8.06 ± 4.84 mg/dL to 5.49 ± 3.39 mg/dL). Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma‐glutamyl transpeptidase were significantly decreased by EMPA. The estimated glomerular filtration rate (from 74.5 ± 16.5 to 71.0 ± 16.2 mL/min/1.73 m^2^) and urinary albumin excretion (measured as the urinary albumin‐to‐creatinine ratio (from 33.3 ± 51.8 to 23.7 ± 35.6 mg/gCr) significantly decreased. However, high‐sensitivity C‐reactive protein and brain natriuretic peptide were not significantly changed at 12 weeks. EMPA treatment for 12 weeks significantly lowered systolic blood pressure, but not diastolic blood pressure. In contrast, in the placebo group, there were no significant differences in these clinical parameters between at baseline and at 12 weeks, except for small but significant increases in AST and ALT.

###### 

Clinical parameters before and after administration of placebo or empagliflozin

                            Placebo (*n* = 51)   EMPA (*n* = 58)                                                                                                 
  ------------------------- -------------------- ----------------- ------ ------------------------------------------------ -------------- -------------- ------- --------------------------------------------------
  BW (kg)                   80.7 ± 10.1          82.55 ± 12.4      2.2    0.146                                            83.55 ± 17.9   80.68 ± 18.4   −3.4    0.001748[\*](#jdi12781-note-0002){ref-type="fn"}
  BMI                       28.8 ± 3.2           29.07 ± 3.24      0.7    0.0522                                           30.7 ± 4.7     29.5 ± 4.8     −3.6    \< 0.001[\*](#jdi12781-note-0002){ref-type="fn"}
  FBG (mg/dL)               130 ± 26.5           127.3 ± 23.9      −2.1   0.326                                            134.7 ± 27.3   124 ± 20.7     −7.9    \< 0.001[\*](#jdi12781-note-0002){ref-type="fn"}
  HbA1c (%)                 6.91 ± 0.61          6.95 ± 0.58       0.5    0.479                                            7.37 ± 1.34    6.97 ± 0.94    −5.4    0.00334[\*](#jdi12781-note-0002){ref-type="fn"}
  IRI (mU/mL)               8.81 ± 3.59          9.15 ± 3.54       3.8    0.432                                            10.59 ± 5.83   9.13 ± 5.5     −13.7   0.00128[\*](#jdi12781-note-0002){ref-type="fn"}
  HOMA‐R                    2.86 ± 0.59          2.98 ± 0.76       4.1    0.486                                            3.03 ± 1.97    2.33 ± 1.95    −23.1   \< 0.001[\*](#jdi12781-note-0002){ref-type="fn"}
  LDL‐C (mg/dL)             119.6 ± 23.3         121.9 ± 21.4      1.9    0.353                                            114.4 ± 29.9   116 ± 27.5     1.8     0.262
  HDL‐C (mg/dL)             54.9 ± 12.8          54.8 ± 10.8       −0.1   0.939                                            55.9 ± 13.8    57.7 ± 14.6    3.2     0.0338[\*](#jdi12781-note-0002){ref-type="fn"}
  TG (mg/dL)                120.6 ± 47.7         123.0 ± 43.2      1.9    0.672                                            144.8 ± 60.8   126.8 ± 43.1   −12.4   0.0104[\*](#jdi12781-note-0002){ref-type="fn"}
  RLP‐C (mg/dL)             7.77 ± 4.93          7.08 ± 4.06       −8.8   0.36                                             8.06 ± 4.84    5.49 ± 3.39    −31.8   0.001302[\*](#jdi12781-note-0002){ref-type="fn"}
  AST (IU/L)                25.9 ± 9.8           28.4 ± 12.1       9.6    0.01[\*](#jdi12781-note-0002){ref-type="fn"}     28.6 ± 13.9    26.1 ± 11.5    −8.7    0.0382[\*](#jdi12781-note-0002){ref-type="fn"}
  ALT (IU/L)                31.8 ± 19.5          38.4 ± 28.1       20.7   0.0214[\*](#jdi12781-note-0002){ref-type="fn"}   35.3 ± 20.4    30.9 ± 19.4    −12.4   0.00958[\*](#jdi12781-note-0002){ref-type="fn"}
  γGTP (IU/L)               48.9 ± 36.8          49.5 ± 34.2       1.2    0.857                                            39.4 ± 23.4    35.5 ± 21.5    −9.8    0.00755[\*](#jdi12781-note-0002){ref-type="fn"}
  eGFR (mL/min/1.73 m^2^)   73.4 ± 18.7          73.7 ± 18.6       0.4    0.755                                            74.5 ± 16.5    71 ± 16.2      −4.6    \< 0.001[\*](#jdi12781-note-0002){ref-type="fn"}
  ACR (mg/gCr)              33.2 ± 66.1          54.7 ± 126        64.7   0.121                                            33.3 ± 51.8    23.7 ± 35.6    −28.8   \< 0.001[\*](#jdi12781-note-0002){ref-type="fn"}
  BNP (pg/mL)               12 ± 8.4             14 ± 7            16     0.236                                            13.4 ± 12.2    12.6 ± 12.2    −5.9    0.541
  hsCRP (mg/L)              0.13 ± 0.14          0.12 ± 0.15       −7.1   0.61                                             0.12 ± 0.11    0.12 ± 0.09    3.3     0.082
  SBP (mmHg)                126.2 ± 15.2         125.7 ± 17.6      −0.3   0.777                                            134.8 ± 15.8   126 ± 15.3     −5.9    \< 0.001[\*](#jdi12781-note-0002){ref-type="fn"}
  DBP (mmHg)                76.6 ± 10.2          75.5 ± 9.6        −1.4   0.37                                             77.7 ± 10.5    75.5 ± 11.9    −2.8    0.0942

Data are expressed as mean ± standard deviation or percent change after treatment. \**P* \< 0.05 (*P*‐values for the intragroup comparison). γGTP, gamma‐glutamyl transpeptidase; ACR, albumin‐to‐creatinine ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI body mass index; BNP, brain natriuretic peptide; BW, bodyweight; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; EMPA, empagliflozin; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; hsCRP, high‐sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; RLP‐C, remnant‐like particle cholesterol; SBP, systolic blood pressure; TG, triglyceride.

John Wiley & Sons, Ltd

Changes from baseline to at 12 weeks in these clinical parameters between the placebo group and the EMPA group were compared (Table [2](#jdi12781-tbl-0002){ref-type="table"}). The mean change was significantly greater for bodyweight, BMI, fasting blood glucose, HbA1c, IRI, HOMA‐IR, RLP‐C, AST, ALT, gamma‐glutamyl transpeptidase, albumin‐to‐creatinine ratio and brain natriuretic peptide in the EMPA group than in the placebo group. However, the mean change was not significantly different for LDL‐C, HDL‐C, triglyceride, estimated glomerular filtration rate and high‐sensitivity C‐reactive protein between the placebo group and the EMPA group. The change in systolic blood pressure, but not in diastolic blood pressure, was significantly different between the two groups.

###### 

Comparison of change in clinical parameters before and after administration of placebo or empagliflozin

                             Placebo        EMPA            *P*‐value
  -------------------------- -------------- --------------- --------------------------------------------------
  ΔBW (kg)                   0.57 ± 1.28    −3.10 ± 2.02    0.001176[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔBMI                       0.32 ± 0.61    −1.11 ± 0.94    0.004555[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔFBG (mg/dL)               −2.6 ± 18.8    −10.9 ± 23.0    0.0448[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔHbA1c (%)                 −0.07 ± 0.37   −0.49 ± 1.1     0.0295[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔIRI (μU/mL)               0.17 ± 0.62    −1.06 ± 0.84    \< 0.001[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔHOMA‐R                    0.1 ± 0.437    −0.54 ± 1.11    0.0105[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔLDL‐C (mg/dL)             4.13 ± 16.0    2.44 ± 15.8     0.695
  ΔHDL‐C (mg/dL)             0.40 ± 6.3     1.4 ± 5.4       0.504
  ΔTG (mg/dL)                −2.0 ± 30.6    −9.2 ± 47.2     0.486
  ΔRLP‐C mg/dL)              0.51 ± 5.5     −0.51 ± 5.5     0.00988[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔAST (IU/L)                2.0 ± 5.9      −2.2 ± 9.7      0.0324[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔALT (IU/L)                3.4 ± 11       −4.3 ± 13       0.0213[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔγGTP (IU/L)               6.0 ± 15       −5.2 ± 17       0.0116[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔeGFR (mL/min/1.73 m^2^)   −1.5 ± 7.1     −3.5 ± 6.1      0.00585[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔACR (mg/gCr)              −0.07 ± 9.6    −12.02 ± 8.4    0.0216[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔBNP (pg/mL)               1.6 ± 7.8      −3.2 ± 9.0      0.0421[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔhsCRP (mg/L)              0.017 ± 0.16   −0.013 ± 0.83   0.432
  ΔSBP (mmHg)                −1.7 ± 8.2     −9.2 ± 12       0.0115[\*](#jdi12781-note-0003){ref-type="fn"}
  ΔDBP (mmHg)                −2.90 ± 6.9    −1.05 ± 10.5    0.409

Data are expressed as mean ± standard deviation. \**P* \< 0.05. γGTP, gamma‐glutamyl transpeptidase; ACR, albumin‐to‐creatinine ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI body mass index; BNP, brain natriuretic peptide; BW, bodyweight; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; EMPA, empagliflozin; FBG, fasting blood glucose; HbA1c, glycated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; hsCRP, high‐sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; RLP‐C, remnant‐like particle cholesterol; SBP, systolic blood pressure; TG, triglyceride. (pvalues for intergroup comparison).

John Wiley & Sons, Ltd

To determine the factors associated with the change in RLP‐C, multiple linear regression analysis was carried out for the EMPA group. In this model, the change in RLP‐C was used as an objective variable, and changes in BMI, HbA1c, HOMA‐IR, AST, ALT, gamma‐glutamyl transpeptidase, LDL‐C, HDL‐C, estimated glomerular filtration rate, systolic blood pressure and treatment or not with statins or fibrates were used as explanation variables. Explanation variables were selected among those that the change from baseline to at 12 weeks was significantly greater than that in the placebo group, except for treatment or not with statins or fibrates. When several variables had a direct relationship to each other, one was selected among them. This analysis (*R* ^2^ = 0.7421, *P* = 0.0006316) showed that the change in HOMA‐IR (*t*‐value = 2.823, *P* = 0.0102) and the change in ALT (*t*‐value = −2.325, *P* = 0.0301) were significantly associated with the change in RLP‐C. The other factors, including treatment or not with statins or fibrates, were not significantly associated with the RLP‐C change (Table [3](#jdi12781-tbl-0003){ref-type="table"}).

###### 

Contributors to the change in remnant‐like particle cholesterol through multiple linear regression coefficients

                             Estimate    Std. error   *t*‐value   *P*‐value
  -------------------------- ----------- ------------ ----------- ------------------------------------------------
  ΔBMI                       0.238806    0.369723     0.643       0.5253
  ΔeGFR (mL/min/1.73 m^2^)   0.031203    0.029639     1.053       0.3044
  ΔγGTP (IU/L)               −0.013788   0.019971     −0.69       0.4975
  ΔAST (IU/L)                0.052287    0.055369     0.944       0.3557
  ΔALT (IU/L)                −0.068618   0.029507     −2.325      0.0301[\*](#jdi12781-note-0004){ref-type="fn"}
  ΔHbA1c (%)                 −0.19907    0.283503     −0.702      0.4903
  ΔHDL‐C (mg/dL)             −0.022251   0.017289     −1.287      0.2121
  ΔHOMA‐IR                   0.515829    0.182713     2.823       0.0102[\*](#jdi12781-note-0004){ref-type="fn"}
  ΔSBP (mmHg)                0.015423    0.014045     1.098       0.2846
  ΔTG (mg/dL)                0.00841     0.006638     1.267       0.2191
  Fibrates (+/−)             1.055769    0.703878     1.5         0.1485
  Statins (+/−)              ‐0.552454   0.421693     ‐1.31       0.2043

*R* ^2^ = 0.7421, *P*‐value = 0.0006316. \**P* \< 0.05. γGTP, gamma‐glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL‐C, high‐density lipoprotein cholesterol; HOMA‐IR, homeostatic model assessment of insulin resistance; SBP, systolic blood pressure; Std., standard; TG, triglyceride.

John Wiley & Sons, Ltd

The change in RLP‐C significantly correlated with the change in HOMA‐IR (Pearson correlation coefficient 0.503, 95% confidence interval 0.199--0.719, *P* = 0.00241), suggesting the causal relationship between RLP‐C and insulin resistance (Figure [1](#jdi12781-fig-0001){ref-type="fig"}).

![The change in remnant‐like particle cholesterol (RLP‐C) significantly correlated with the change in homeostatic model assessment of insulin resistance (HOMA‐IR; Pearson correlation coefficient 0.503, 95% confidence interval 0.199--0.719; *P* = 0.00241) in empagliflozin group.](JDI-9-870-g001){#jdi12781-fig-0001}

Discussion {#jdi12781-sec-0012}
==========

The major findings in the present study were that EMPA decreased RLP‐C in fasting serum, which is significantly associated with decreases in HOMA‐IR and ALT. RLP particles have been reported to be elevated in diabetes patients[7](#jdi12781-bib-0007){ref-type="ref"}. RLP‐C is also known to be elevated in metabolic syndrome[8](#jdi12781-bib-0008){ref-type="ref"}. RLP‐C appears to be higher in individuals with insulin resistance, and it is indeed reported that HOMA‐IR is closely related to RLP‐C during medical examination[9](#jdi12781-bib-0009){ref-type="ref"}, [10](#jdi12781-bib-0010){ref-type="ref"}. In the present study, RLP‐C levels in fasting serum were higher at baseline in both the placebo group and EMPA group, and the enrolled participants in both groups had insulin resistance. RLP‐C levels decreased after the administration of EMPA, but not of a placebo for 12 weeks. In the EMPA group, multiple regression analysis showed that the change in HOMA‐IR and the change in ALT were significantly associated with the change in RLP‐C. Several reports have shown that SGLT2 inhibitors ameliorate peripheral insulin resistance in humans[11](#jdi12781-bib-0011){ref-type="ref"}, [12](#jdi12781-bib-0012){ref-type="ref"}. Thus, the present findings suggest that the EMPA‐associated decrease in RLP‐C is closely related to the EMPA‐mediated improvement in insulin resistance. Remnant lipoproteins are taken up and metabolized by the liver. The EMPA‐mediated decrease in ALT could reflect a reduction in liver fat content, which might activate the uptake and metabolism of remnant lipoproteins in liver.

Recently, it was reported that dapagliflozin decreases small dense LDL‐C and increases HDL2‐C in patients with type 2 diabetes[13](#jdi12781-bib-0013){ref-type="ref"}. In that study, RLP‐C levels were not significantly changed before and after the administration of dapagliflozin. It is unclear why the present results differ from those reported for dapagliflozin. It is possible that the beneficial effect on RLP‐C observed in the present study could be a unique feature of EMPA, or it could be attributed to differences in study participants.

Finally, remnant lipoproteins are thought to be atherogenic, and higher levels of remnant lipoproteins are indeed reported to predict future coronary events in patients with coronary artery disease, independent of other risk factors[14](#jdi12781-bib-0014){ref-type="ref"}. The enigma from the EMPA‐REG OUTCOME^®^ study is that the CV benefits occur as early as 3 months after initiation of the administration of EMPA, and that there is no reduction in traditional atherothrombolic CV events[15](#jdi12781-bib-0015){ref-type="ref"}. However, EMPA‐mediated improvement of RLP‐C might contribute to the diminishment of future coronary events in diabetes patients.

The present study had several limitations. EMPA is reported to improve insulin sensitivity, as determined using tracer glucose[11](#jdi12781-bib-0011){ref-type="ref"}. Dapagliflozin has also been shown to improve muscle insulin sensitivity, as determined by euglycemic insulin clamp studies[12](#jdi12781-bib-0012){ref-type="ref"}. We chose HOMA‐IR to evaluate insulin resistance. However, HOMA‐IR is not a good indicator when the patients examined are poorly controlled, whose fasting glucose levels are relatively high and/or fasting IRI might be already exhausted. Another problem is that as SGLT2 inhibitors inhibit the reabsorption of glucose in the proximal tubules of the kidney, leading to increased urinary excretion of glucose and decreased levels of blood glucose in diabetes patients, HOMA‐IR measurements just after the use of EMPA might not always reflect insulin resistance. Thus, we excluded poorly controlled patients from the present study, and at 12 weeks after initiating the administration of EMPA, the administration of EMPA was stopped temporally for 72 h until SGLT2 inhibition was totally ineffective, then blood glucose and IRI in fasting blood samples were measured to calculate HOMA‐IR as at 12 weeks in the EMPA group. As this is a small‐sized study, further studies, including direct evaluation of insulin sensitivity, are required to establish the relationship between RLP‐C and insulin resistance.
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